Key result
Administration of 180 mg intravenous sugammadex was followed by severe bradycardia progressing to pulseless electrical activity cardiac arrest in a 68-year-old man.
Why the study?
Sugammadex-induced bradycardia has been previously described, but its mechanism remains unknown, prompting this report to promote awareness of this potential complication.
Case Report (n=1)
No
Sugammadex administration can potentially cause severe bradycardia progressing to pulseless electrical activity cardiac arrest.
Sugammadex may cause refractory bradycardia and arrest; this Level 5 case leaves causality and risk unproven.
A 68-year-old man underwent elective surgical repair of an abdominal wall hernia under general anaesthesia. The operation required muscle relaxation, for which we used rocuronium. Following completion of surgery, 180 mg sugammadex was administered intravenously. Shortly afterwards, the patient became severely bradycardic with hypotension, refractory to treatment with ephedrine. This progressed to a pulseless electrical activity cardiac arrest. After 4 min of cardiopulmonary resuscitation, there was return of spontaneous circulation and, following a period of haemodynamic stability in which general anaesthesia was maintained, the patient emerged from anaesthesia without incident. He remained haemodynamically stable until discharge. Post-resuscitation investigations including the serum tryptase level were unremarkable except for a mild respiratory acidosis and slightly elevated D-dimers. Sugammadex-induced bradycardia has previously been described, but its mechanism remains unknown. We believe that sugammadex was the cause of cardiac arrest in this case because of the timing and sequence of events, the evolution to pulseless electric activity and the relatively uneventful post-arrest clinical course. We hope that our report will help to promote awareness about this potential complication of a now commonly-used drug.
No takes yet. Share an insight, caveat, or question.
Pereira et al. (2023) conducted a case report in Abdominal wall hernia (n=1). Sugammadex was evaluated on Cardiac arrest. Administration of 180 mg intravenous sugammadex was followed by severe bradycardia progressing to pulseless electrical activity cardiac arrest in a 68-year-old man.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: